June 8, 2020
Meiji Seika Pharma said on June 5 that it will terminate the development of its investigational nail ringworm treatment ME1111 after disappointing Japan PII results. ME1111 is an antifungal originated by Meiji Seika Pharma, the pharma arm of confectionary maker...read more